Published: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 476 to 500 of 881

Sort by

Guidance programme: Technology appraisal guidanceRemove Guidance programme: Technology appraisal guidance filter

Published guidance, NICE advice and quality standards
Title	Reference number	Published	Last updated
Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant	TA640	5 August 2020	5 August 2020
Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer	TA639	1 July 2020	1 July 2020
Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer	TA638	1 July 2020	1 July 2020
Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal)	TA635	30 June 2020	30 June 2020
Eculizumab for treating refractory myasthenia gravis (terminated appraisal)	TA636	30 June 2020	30 June 2020
Ranibizumab for treating diabetic retinopathy (terminated appraisal)	TA637	30 June 2020	30 June 2020
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal)	TA634	30 June 2020	30 June 2020
Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure	TA626	24 June 2020	24 June 2020
Ustekinumab for treating moderately to severely active ulcerative colitis	TA633	17 June 2020	17 June 2020
Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer	TA632	10 June 2020	10 June 2020
Larotrectinib for treating NTRK fusion-positive solid tumours	TA630	27 May 2020	27 May 2020
Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer	TA628	13 May 2020	13 May 2020
Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab	TA629	13 May 2020	13 May 2020
Lenalidomide with rituximab for previously treated follicular lymphoma	TA627	7 April 2020	7 April 2020
Recombinant human parathyroid hormone for treating hypoparathyroidism (terminated appraisal)	TA625	4 March 2020	4 March 2020
Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis	TA624	19 February 2020	19 February 2020
Patiromer for treating hyperkalaemia	TA623	13 February 2020	13 February 2020
Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal)	TA618	15 January 2020	15 January 2020
Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure	TA617	8 January 2020	8 January 2020
Cannabidiol with clobazam for treating seizures associated with Dravet syndrome	TA614	18 December 2019	18 December 2019
Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome	TA615	18 December 2019	18 December 2019
Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab	TA612	20 November 2019	20 November 2019
Pentosan polysulfate sodium for treating bladder pain syndrome	TA610	13 November 2019	13 November 2019
Ibrutinib with rituximab for treating Waldenstrom's macroglobulinaemia (terminated appraisal)	TA608	30 October 2019	30 October 2019
Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal)	TA609	30 October 2019	30 October 2019

Results per page

10
25
50
All